Regulus Therapeutics, Inc.

Regulus Therapeutics, Inc.

Regulus Therapeutics, Inc.

Overview
Date Founded

2007

Headquarters

4224 Campus Point Court,Suite 210,San Diego, CA 92121

Type of Company

Public

Employees (Worldwide)

24

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Regulus Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer & Director

Chief Financial Officer

Secretary, Senior Vice President & General Counsel

Chief Scientific Officer

Controller & Principal Accounting Officer

Senior Vice President, Human Capital

Vice President, Pharmaceutical Development

Vice President, Pharmaceutical Development

Leader

Director

Board of Directors

Co-Founder at Exelixis, Inc.

Former Interim Chief Executive Officer at Fate Therapeutics, Inc.

President Emeritus at California Institute of Technology

Senior Faculty Associate in Biology at California Institute of Technology

Venture Advisor at New Enterprise Associates, Inc.

Founder at PWH Advisors

Chairman & President at ActivX Biosciences, Inc.

Vice President, Audit Services at Sempra Energy

Partner/Senior Managing Director at Sarissa Capital Management LP

Paths to Regulus Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Regulus Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Endurant Capital Management seeks to generate steady, risk-adjusted returns through long/short investments in small- to mid-cap growth companies in the healthcare sector. The firm’s fund and sub-advised accounts invest principally, but not solely, in equity and equity-related securities that are traded publicly in US markets.

Details Hidden

Asymmetry Capital Management seeks to deliver absolute, risk-adjusted returns across market cycles by investing in a value-oriented, diversified, global portfolio of healthcare companies. The firm's objective is to generate returns on both long and short positions with moderate to low net exposure and low correlations to broad equity and healthcare-related indices. Asymmetry also focuses on maximizing positive and sustainable impacts on ESG (environment, social and governance) and responsible investing.

Details Hidden

Endurant Capital Management seeks to generate steady, risk-adjusted returns through long/short investments in small- to mid-cap growth companies in the healthcare sector. The firm’s fund and sub-advised accounts invest principally, but not solely, in equity and equity-related securities that are traded publicly in US markets.

Recent Transactions
Details Hidden

Regulus Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Regulus Therapeutics, Inc. issued USD Common Stock

Details Hidden

Regulus Therapeutics, Inc. issued USD Common Stock

Transaction Advisors
Underwriter

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Managing Director

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Professional

Advised onRegulus Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Advisor

Co-Founder at Alnylam Pharmaceuticals, Inc.

Legal Advisor

Partner, San Diego at Cooley LLP

Advisor

President Emeritus at California Institute of Technology

Clients

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Key Stats and Financials As of 2020
Market Capitalization
$34.1M
Total Enterprise Value
$21.3M
Earnings Per Share
$-0.45
Revenue
$10M
Net Profit
$-15.7M
EBITDA
$-13.7M
EBITDAMargin
-136.8%
Total Debt
$5.12M
Total Equity
$26M
Enterprise Value / Sales
2.12x
TEVNet Income
-1.35x
Debt TEV
0.24x
Three Year Compounded Annual Growth Rate Of Revenue
417.97%
Suppliers
Alnylam Pharmaceuticals, Inc. Medical Support Services | Cambridge, Massachusetts

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Ionis Pharmaceuticals, Inc. Hospitals & Patient Services | Carlsbad, California

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Competitors
Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Regulus Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Regulus Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Regulus Therapeutics, Inc..